BACKGROUND: Colorectal cancers diagnosed in the interval after a complete colonoscopy may occur due to rapid tumor growth. Interval colorectal cancers are associated with microsatellite instability (MSI). AIMS: Our aim was to study the association of KRAS mutation with interval colorectal cancers and MSI. METHODS: We searched our institution's cancer registry for interval colorectal cancers, defined as colorectal cancers that developed within 5 years of a complete colonoscopy. These were frequency matched to patients with non-interval colorectal cancers. Archived cancer specimens were evaluated for KRAS mutations in codons 12 and 13 using sequencing, and MSI by sequencing microsatellite loci. Multivariable logistic regression was used to analyze the association between KRAS mutation status, MSI status and interval colorectal cancers. RESULTS: There were 63 interval and 131 non-interval colorectal cancers. KRAS mutation was present in 12.9% of interval cancers compared to 28.9% of non-interval cancers (P = 0.03). In multivariable logistic regression model, KRAS was inversely associated with interval cancers (OR 0.36; 95% CI 0.15-0.90). In Cox proportional hazards model, adjusting for age, tumor grade, TNM Stage and MSI status, we found no association between KRAS mutation and 5-year survival compared to cancers without KRAS mutation (HR 0.84; 95% CI 0.4-1.46; P = 0.5). CONCLUSIONS: KRAS mutation is inversely associated with interval cancers and with MSI, suggesting that it is a marker of the chromosomal instability pathway associated with slow tumor growth, and distinct from MSI rapidly growing cancers. Molecular characterization of colorectal cancers is helpful in determining underlying pathway and may determine therapy.
BACKGROUND:Colorectal cancers diagnosed in the interval after a complete colonoscopy may occur due to rapid tumor growth. Interval colorectal cancers are associated with microsatellite instability (MSI). AIMS: Our aim was to study the association of KRAS mutation with interval colorectal cancers and MSI. METHODS: We searched our institution's cancer registry for interval colorectal cancers, defined as colorectal cancers that developed within 5 years of a complete colonoscopy. These were frequency matched to patients with non-interval colorectal cancers. Archived cancer specimens were evaluated for KRAS mutations in codons 12 and 13 using sequencing, and MSI by sequencing microsatellite loci. Multivariable logistic regression was used to analyze the association between KRAS mutation status, MSI status and interval colorectal cancers. RESULTS: There were 63 interval and 131 non-interval colorectal cancers. KRAS mutation was present in 12.9% of interval cancers compared to 28.9% of non-interval cancers (P = 0.03). In multivariable logistic regression model, KRAS was inversely associated with interval cancers (OR 0.36; 95% CI 0.15-0.90). In Cox proportional hazards model, adjusting for age, tumor grade, TNM Stage and MSI status, we found no association between KRAS mutation and 5-year survival compared to cancers without KRAS mutation (HR 0.84; 95% CI 0.4-1.46; P = 0.5). CONCLUSIONS:KRAS mutation is inversely associated with interval cancers and with MSI, suggesting that it is a marker of the chromosomal instability pathway associated with slow tumor growth, and distinct from MSI rapidly growing cancers. Molecular characterization of colorectal cancers is helpful in determining underlying pathway and may determine therapy.
Authors: Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs Journal: Gut Date: 2008-10-02 Impact factor: 23.059
Authors: Shuji Ogino; Jeffrey A Meyerhardt; Takako Kawasaki; Jeffrey W Clark; David P Ryan; Matthew H Kulke; Peter C Enzinger; Brian M Wolpin; Massimo Loda; Charles S Fuchs Journal: Virchows Arch Date: 2007-03-20 Impact factor: 4.064
Authors: Wade S Samowitz; Carol Sweeney; Jennifer Herrick; Hans Albertsen; Theodore R Levin; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery Journal: Cancer Res Date: 2005-07-15 Impact factor: 12.701
Authors: Mandeep S Sawhney; William D Farrar; Srivani Gudiseva; Douglas B Nelson; Frank A Lederle; Thomas S Rector; John H Bond Journal: Gastroenterology Date: 2006-12 Impact factor: 22.682
Authors: James M Richter; Maria Simona Pino; Thomas R Austin; Emily Campbell; Jackie Szymonifka; Andrea L Russo; Theodore S Hong; Darrell Borger; A John Iafrate; Daniel C Chung Journal: Dig Dis Sci Date: 2014-04-05 Impact factor: 3.199
Authors: A L Cisyk; S Penner-Goeke; Z Lichtensztejn; Z Nugent; R H Wightman; H Singh; K J McManus Journal: Neoplasia Date: 2015-03 Impact factor: 5.715
Authors: Y Zhu; S R Yang; P P Wang; S Savas; T Wish; J Zhao; R Green; M Woods; Z Sun; B Roebothan; J Squires; S Buehler; E Dicks; J Zhao; J R Mclaughlin; P S Parfrey; P T Campbell Journal: Br J Cancer Date: 2014-01-21 Impact factor: 7.640
Authors: M Garcia; X Domènech; C Vidal; E Torné; N Milà; G Binefa; L Benito; V Moreno Journal: Gastroenterol Res Pract Date: 2015-02-24 Impact factor: 2.260
Authors: Reiko Nishihara; Kana Wu; Paul Lochhead; Teppei Morikawa; Xiaoyun Liao; Zhi Rong Qian; Kentaro Inamura; Sun A Kim; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Walter C Willett; Bernard A Rosner; Charles S Fuchs; Edward Giovannucci; Shuji Ogino; Andrew T Chan Journal: N Engl J Med Date: 2013-09-19 Impact factor: 91.245
Authors: Kyeong Ok Kim; Kyu Chan Huh; Sung Pil Hong; Won Hee Kim; Hyuk Yoon; Sang Wook Kim; Yeon Soo Kim; Jong Ha Park; Jun Lee; Bum Jae Lee; Young Sook Park Journal: Gut Liver Date: 2018-09-15 Impact factor: 4.519